Health Alert:

COVID-19 Vaccine Information and Updates

FDA-approved CAR T-cell Therapies

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a patient’s own genetically modified T cells to find and kill cancer. UPMC Hillman Cancer Center currently offers two types of FDA-approved CAR T-cell therapy.

ABECMA® (idecabtagene vicleucel)

UPMC Hillman Cancer Center was one of the first in the United States certified to provide ABECMA® (idecabtagene vicleucel) for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an antidCD38 monoclonal antibody.


Hillman was the first of 10 centers in the United States to offer BREYANZI® (lisocabtagene maraleucel), an FDA-approved CAR T-cell therapy for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including:

  • Diffuse large B cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma)
  • High-grade B-cell lymphoma
  • Primary mediastinal large B-cell lymphoma
  • Follicular lymphoma grade 3B


UPMC Hillman Cancer Center was the first in western Pennsylvania to provide TECARTUS TM (brexucabtagene autoleucel), an FDA-approved CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma. Hillman also provides TECARTUS for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).


UPMC Hillman Cancer Center is part of the network of certified treatment centers providing KYMRIAHTM (tisagenlecleucel), an FDA-approved CAR T-cell therapy for:

  • Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • Young adult patients up to age 25 with relapsed or refractory acute lymphoblastic leukemia (ALL)


UPMC Hillman Cancer Center is the first center in western Pennsylvania providing YESCARTATM (axicabtagene ciloleucel), the first FDA-approved CAR T-cell therapy for adult patients with certain types of B-cell lymphoma.

The FDA has approved this treatment for patients with the following conditions that have either not responded to or have relapsed following two or more lines of systemic therapy:

  • Diffuse large B-cell lymphoma (DLBCL)
  • Primary mediastinal B-cell lymphoma
  • High grade B-cell lymphoma
  • DLBCL that results from follicular lymphoma
  • Follicular lymphoma

Patients will undergo an extensive evaluation to determine their eligibility for this highly specialized treatment. To learn more, please call 1-833-UPMC-CART.

What to Expect from CAR T-Cell Therapy

Patients who are approved for CAR T-cell therapy will undergo the following treatment process:

  • Collection: Patients undergo leukapheresis at the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center. During this process, white blood cells (including T cells) are collected from the patient.
  • Modification: Our team sends the collected cells to the manufacturing laboratory, where they are genetically modified to express chimeric antigen receptors (CARs) on their surface.
  • Multiplication: The genetically modified T cells are grown in the lab, multiplying so they increase in number. The lab freezes the multiplied cells and ships them back to UPMC Hillman Cancer Center; this process takes about 2-3 weeks.
  • Chemotherapy: Patients will receive conditioning chemotherapy a few days prior to their hospital admission for infusion. This therapy improves the ability of the infused CAR T cells to expand and multiply.
  • Infusion and Inpatient Hospitalization: Patients are admitted at UPMC Shadyside and the CAR T cells are infused back into their bloodstream in a single infusion, like a blood transfusion. Patients typically stay in the hospital for 1-2 weeks following infusion so our team can closely monitor them for potential side effects.
  • Recovery: The risk/recovery period following CAR T-cell therapy is usually 2-3 months. During this period, patients must be monitored for side effects and treatment response, which can be severe. The U.S. Food and Drug Administration requires patients treated with CAR T-cell therapy to remain near UPMC Hillman Cancer Center during the initial 30-day acute recovery period.

Contact Us

Physician Referrals

To refer a patient for evaluation for one of these clinical trials, please call 1-833-876-2227 (1-833-UPMC-CART).


If you think you might be a candidate for one of these clinical trials, please call 1-833-876-2227 (1-833-UPMC-CART).